
## SUPPLEMENTAL MATERIALS

## TABLE OF CONTENTS

Figure S1. Distribution of eGFR values at baseline in patients with baseline eGFR <30	
$mL/min/1.73m^2$	. 2
Figure S2. Forest plots for the prespecified exploratory endpoints by baseline CKD stage	. 3
Figure S3. Forest plots for the <i>post-hoc</i> exploratory endpoints by baseline CKD stage	. 4

**Figure S1.** Distribution of eGFR values at baseline in patients with baseline eGFR <30 mL/min/1.73m<sup>2</sup>



All participants whose baseline eGFR was  $<\!25$  mL/min/1.73m<sup>2</sup> (n=60) had screening eGFR 25-75 mL/min/1.73m<sup>2</sup> as per the inclusion criteria.

Figure S2. Forest plots for the prespecified exploratory endpoints by baseline CKD stage

	Dapagliflozi					Hazard Ratio (95% CI)	P Value for Interaction	Absolute Risk Difference, %	P Value for Interaction
	n	/N	Events/100 p	batterit-year	S			(95% CI)	
Dialysis, kidney tr	ansplantation o	or kidney de	ath		!				
Overall	71/2152	103/2152	1.5	2.3	<b>⊷</b> ⊶¦	0.66 (0.49, 0.90)		1.5 (0.3, 2.7)	
Stage 4 CKD	30/293	40/331	5.0	6.2	<b>⊢•</b> ∔	0.77 (0.48, 1.24)	0.49	1.8 (-3.1, 6.8)	0.80
Stage 2/3 CKD	41/1859	63/1821	1.0	1.6	<b>⊢</b>	0.63 (0.42, 0.93)		1.3 (0.2, 2.3)	
CV death, myocai	rdial infarction o	or stroke							
Overall	132/2152	143/2152	2.9	3.1	<b>⊢</b> • <u>i</u> ·	0.92 (0.72, 1.16)		0.5 (-1.0, 2.0)	
Stage 4 CKD	19/293	31/331	3.1	4.7	<del></del>	0.66 (0.37, 1.17)	0.20	2.9 (-1.3, 7.1)	0.22
Stage 2/3 CKD	113/1859	112/1821	2.9	2.9	<b>+</b>	0.99 (0.76, 1.28)		0.1 (-1.5, 1.6)	
First heart failure	hospitalization								
Overall	37/2152	71/2152	0.8	1.6	<b></b>	0.51 (0.34, 0.76)		1.6 (0.6, 2.5)	
Stage 4 CKD	6/293	12/331	1.0	1.8 ⊢	<del></del>	0.52 (0.20, 1.39)	0.90	1.6 (-1.0, 4.2)	0.99
Stage 2/3 CKD	31/1859	59/1821	0.8	1.5	<b></b>	0.50 (0.33, 0.78)		1.6 (0.6, 2.6)	
				0.2	0.5 1 2.0	5.0			
				<b> ✓</b> Dapag	liflozin Better Placebo	Better			

 $CI, confidence\ intervals;\ CV,\ cardiovascular;\ ESKD,\ end-stage\ kidney\ disease;\ n,\ number\ with\ events;\ N,\ total\ number.$ 

Figure S3. Forest plots for the *post-hoc* exploratory endpoints by baseline CKD stage

	Dapagliflozin Placebo		Dapagliflozin Placebo				<b>Hazard Ratio</b>	P Value for	Absolute Risk	P Value for
	n.	/N	Events/100 p	atient-years			(95% CI)	Interaction	Difference, % (95% CI)	Interaction
ESKD or all-cause	e death									
Overall	194/2152	280/2152	4.5	6.6			0.67 (0.56, 0.81)		4.0 (2.1, 5.9)	
Stage 4 CKD	63/293	95/331	11.9	16.3	<b>⊢</b> ⊷-i		0.72 (0.52, 0.99)	0.73	7.2 (0.4, 14.0)	0.23
Stage 2/3 CKD	131/1859	185/1821	3.5	5.0	⊷		0.68 (0.54, 0.85)		3.1 (1.3, 4.9)	
ESKD or heart fai	lure hospitaliza	tion								
Overall	141/2152	221/2152	3.3	5.3			0.61 (0.49, 0.75)		3.7 (2.1, 5.4)	
Stage 4 CKD	53/293	79/331	10.0	13.7	<b>—</b>		0.69 (0.49, 0.98)	0.39	5.8 (-0.6, 12.1)	0.39
Stage 2/3 CKD	88/1859	142/1821	2.3	3.9			0.59 (0.45, 0.76)		3.1 (1.5, 4.6)	
ESKD, myocardia	I infarction, stro	ke, heart fa	ilure hospitaliz	ation or CV	death					
Overall	250/2152	333/2152	5.9	8.1	<b>⊢</b>		0.72 (0.61, 0.85)		3.9 (1.8, 5.9)	
Stage 4 CKD	66/293	103/331	12.7	18.4	<b></b> ¦		0.68 (0.49, 0.92)	0.55	8.6 (1.7, 15.5)	0.10
Stage 2/3 CKD	184/1859	230/1821	5.0	6.4	H		0.76 (0.63, 0.93)		2.7 (0.7, 4.8)	
All-cause death, E	ESKD or heart f	ailure hospi	talization							
Overall	222/2152	327/2152	5.2	7.8	<del>⊢•</del> ⊣		0.65 (0.55, 0.78)		4.9 (2.9, 6.9)	
Stage 4 CKD	66/293	99/331	12.5	17.2	<b>⊢</b> •–-;		0.70 (0.51, 0.96)	0.58	7.4 (0.5, 14.3)	0.36
Stage 2/3 CKD	156/1859	228/1821	4.1	6.3	<b>⊢</b>		0.65 (0.53, 0.79)		4.1 (2.2, 6.1)	
				0.2	0.5 1	2.0 5.0	)			
				Dapagli	flozin Better I	Placebo Better				

CI, confidence intervals; CV, cardiovascular; ESKD, end-stage kidney disease; n, number with events; N, total number.